Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 18, 2009. The report discloses a notifiable share interest transaction involving Algeta ASA, a Norwegian oncology company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction.
- Transaction Date: September 18, 2009
- Shares Sold: 274,800 ordinary shares of Algeta ASA
- Remaining Holding: 1,697,800 ordinary shares
- Remaining Ownership Percentage: 4.313% of Algeta ASA
- Trigger for Disclosure: The holding fell below the 5% threshold required under the Norwegian Securities Trading Act.
Material Changes
The material change reported is the reduction of GSK's stake in Algeta ASA from above 5% to 4.313%. This reduction was executed by S.R. One, Limited, a wholly owned US-registered subsidiary of GSK.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific share sale transaction.
Key Facts for Investor Verification
- Verify the current market price of Algeta ASA shares on the Oslo Stock Exchange to assess the value of the remaining 4.313% stake.
- Confirm the total number of outstanding shares in Algeta ASA (stated as 39,351,082) to validate the ownership percentage calculation.
- Review subsequent filings to determine if GSK intends to further reduce or increase its position in Algeta ASA.